Join AsymBio at the BIO International Convention (Booth 1785) held in Boston Convention and Exhibition Center on June 16-19 to discuss how AsymBio can advance your molecules from early stage development to commercial manufacturing with our industry leading integrated CDMO solutions!

AsymBio team is heading to Antibody Engineering much more!

Meet our experts at booth #5 at 4th World ADC Asia Summit at Incheon to know more about our integrated CDMO solutions for bioconjugates! The 4th World ADC Asia Summit is the must-attend event in Asia for anyone involved in ADC development. This is the only event offering unparalleled depth and brea...

Meet team at Booth #10 of Bio Integrates 2025!Date: May 20th, 2025 Location: Anglia Ruskin University, Cambridge, UKBio Integrates addresses the needs of innovative companies developing the therapies of the future, providing a distinguished forum to discuss the current challenges impacting the biot...

Join AsymBio at 4th ADC Analytical Development Summit in Boston on April 28-30, 2025! AsymBio will take this chance to show how cutting-edge analytical tools are revolutionizing bioassays, enhancing potency measurement, and unlocking deeper insights into ADC mechanisms of action.

Meet AsymBio Team at Booth 635 in Festival of Biologics San Diego 2025!With over 2,000 attendees, 300 speakers, more than 120 exhibitors, and 50 startups in FOB San Diego 2025, AsymBio will showcase industry leading CDMO solutions! Whether you’re tackling complex PD challenges or scaling up producti...

AsymBio, the subsidiary of Asymchem Laboratories (Stock Code: 002821.SZ/6821.HK), announced the official inauguration of its CDMO base in Fengxian, Shanghai. This facility will provide late-stage clinical and commercial manufacturing services for antibodies and bioconjugates.Spanning over 120,000 sq...

Mark your calendars for March 3rd–6th, 2025. AsymBio will be at Booth #36 to showcase cutting-edge integrated solutions for your bioconjugates! Whether you’re tackling complex PD challenges or scaling up production, our experts are ready to collaborate and innovate with you. Do not miss this chance ...

Axcynsis Therapeutics, a strategic partner of AsymBio, announced the clearance of its Investigational New Drug application (IND) by the United States Food and Drug Administration (FDA) of AT03-65 for the treatment of patients with CLDN-6 positive solid tumors. Axcynsis is planning to initiate a Phas...

Novatim, a strategic partner of AsymBio, announced U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the worlds 𝗳𝗶𝗿𝘀𝘁 𝗔𝗗𝗖 with a 𝗯𝗶𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗻𝗮𝗻𝗼𝗯𝗼𝗱𝘆 targeting MET and EGFR. With this IND approval, Novatim will be able to...